153 related articles for article (PubMed ID: 36187518)
1. Post-treatment Residual Clinicopathological Outcomes in Testicular Germ Cell Tumours.
Nagaraj RV; Rao BV; Yoganarsimha J; Fonseca D; Kodandapani S; Giridhar A; Sharma R; Rajappa S; Rao TS; Sundaram C
Indian J Surg Oncol; 2022 Sep; 13(3):505-510. PubMed ID: 36187518
[TBL] [Abstract][Full Text] [Related]
2. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
3. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
4. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
5. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
6. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
[TBL] [Abstract][Full Text] [Related]
7. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
[TBL] [Abstract][Full Text] [Related]
9. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
10. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience.
Tamhankar AS; Patil SR; Ojha SP; Ahluwalia P; Gautam G
J Robot Surg; 2019 Dec; 13(6):747-756. PubMed ID: 30656537
[TBL] [Abstract][Full Text] [Related]
12. Blood testis barrier revisited-Analysis of post-chemotherapy germ cell tumor orchidectomy and retroperitoneal lymph node dissection specimens.
Gupta A; Noronha J; Bakshi G; Menon S; Pal M; Joshi A; Prabash K; Noronha V; Murthy V; Krishnattry R; Patil A; Prakash GJ
J Surg Oncol; 2021 Mar; 123(4):1157-1163. PubMed ID: 33428791
[TBL] [Abstract][Full Text] [Related]
13. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymph node dissection after chemotherapy.
Winter C; Raman JD; Sheinfeld J; Albers P
BJU Int; 2009 Nov; 104(9 Pt B):1404-12. PubMed ID: 19840021
[TBL] [Abstract][Full Text] [Related]
15. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?
Herr HW
Br J Urol; 1997 Oct; 80(4):653-7. PubMed ID: 9352708
[TBL] [Abstract][Full Text] [Related]
16. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
[TBL] [Abstract][Full Text] [Related]
17. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
18. Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patients.
Goepel M; Recker F; Otto T; Krege S; Rübben H
Urol Int; 1996; 57(4):209-12. PubMed ID: 8961487
[TBL] [Abstract][Full Text] [Related]
19. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis.
Nitta S; Kawai K; Kimura T; Kandori S; Kawahara T; Kojima T; Nishiyama H
Int J Urol; 2021 Aug; 28(8):840-847. PubMed ID: 34085325
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours.
Heidenreich A; Haidl F; Paffenholz P; Pape C; Neumann U; Pfister D
Ann Oncol; 2017 Feb; 28(2):362-367. PubMed ID: 27831507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
